Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$23.0 - $31.04 $915,400 - $1.24 Million
-39,800 Reduced 11.28%
313,000 $7.93 Million
Q1 2024

May 15, 2024

BUY
$27.35 - $40.45 $831,440 - $1.23 Million
30,400 Added 9.43%
352,800 $10.9 Million
Q4 2023

Feb 14, 2024

SELL
$24.02 - $43.89 $86,472 - $158,004
-3,600 Reduced 1.1%
322,400 $13 Million
Q3 2023

Nov 14, 2023

SELL
$16.89 - $35.01 $3.75 Million - $7.78 Million
-222,300 Reduced 40.54%
326,000 $8.6 Million
Q2 2023

Aug 14, 2023

BUY
$13.29 - $18.01 $4.12 Million - $5.59 Million
310,300 Added 130.38%
548,300 $9.43 Million
Q1 2023

May 15, 2023

BUY
$7.17 - $18.55 $1.27 Million - $3.29 Million
177,200 Added 291.45%
238,000 $3.95 Million
Q4 2022

Feb 14, 2023

BUY
$6.74 - $11.52 $207,592 - $354,816
30,800 Added 102.67%
60,800 $463,000
Q3 2022

Nov 14, 2022

SELL
$7.94 - $12.36 $172,298 - $268,212
-21,700 Reduced 41.97%
30,000 $298,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.78B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.